Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
Keunchil Park, Gee‐Chen Chang, Giuseppe Curigliano, Wan‐Teck Lim, Ross A. Soo, Miguel Ángel Molina‐Vila, Valérie Cattan, Hélène Darville, E. Gandossi, Veronika Smutná, Isabelle Sudey, Santiago Viteri
Topics & Concepts
GefitinibMedicineT790MTolerabilityLung cancerInternal medicineOncologyTyrosine-kinase inhibitorEpidermal growth factor receptorResponse Evaluation Criteria in Solid TumorsConcomitantCancerChemotherapyProgressive diseaseAdverse effectLung Cancer Treatments and MutationsLiver physiology and pathologyPhagocytosis and Immune Regulation